Cargando…

Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases

BACKGROUND: We prospectively reviewed response rates, local control, and side effects after non-fractionated stereotactic high single-dose body radiation therapy for lung tumors. METHODS: Fifty-eight patients underwent radiosurgery involving single-dose irradiation. With 25 patients, 31 metastases i...

Descripción completa

Detalles Bibliográficos
Autores principales: Fritz, Peter, Kraus, Hans-Jörg, Mühlnickel, Werner, Hammer, Udo, Dölken, Wolfram, Engel-Riedel, Walburga, Chemaissani, Assad, Stoelben, Erich
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1579222/
https://www.ncbi.nlm.nih.gov/pubmed/16919172
http://dx.doi.org/10.1186/1748-717X-1-30
_version_ 1782130313690873856
author Fritz, Peter
Kraus, Hans-Jörg
Mühlnickel, Werner
Hammer, Udo
Dölken, Wolfram
Engel-Riedel, Walburga
Chemaissani, Assad
Stoelben, Erich
author_facet Fritz, Peter
Kraus, Hans-Jörg
Mühlnickel, Werner
Hammer, Udo
Dölken, Wolfram
Engel-Riedel, Walburga
Chemaissani, Assad
Stoelben, Erich
author_sort Fritz, Peter
collection PubMed
description BACKGROUND: We prospectively reviewed response rates, local control, and side effects after non-fractionated stereotactic high single-dose body radiation therapy for lung tumors. METHODS: Fifty-eight patients underwent radiosurgery involving single-dose irradiation. With 25 patients, 31 metastases in the lungs were irradiated; with each of 33 patients, stage I non-small cell lung cancer (NSCLC) was subject to irradiation. The standard dose prescribed to the isocenter was 30 Gy with an axial safety margin of 10 mm and a longitudinal safety margin of 15 mm. The planning target volume (PTV) was defined using three CT scans with reference to the phases of respiration so that the movement span of the clinical target volume (CTV) was enclosed. RESULTS: The volume of the metastases (CTV) varied from 2.8 to 55.8 cm(3 )(median: 6.0 cm(3)) and the PTV varied from 12.2 to 184.0 cm(3 )(median: 45.0 cm(3)). The metastases ranged from 0.7 to 4.5 cm in largest diameter. The volume of the bronchial carcinomas varied from 4.2 to 125.4 cm(3)(median: 17.5 cm(3)) and the PTV from 15.6 to 387.3 cm(3 )(median: 99.8 cm(3)). The bronchial carcinomas ranged from 1.7 to 10 cm in largest diameter. Follow-up periods varied from 6.8 to 63 months (median: 22 months for metastases and 18 months for NSCLC). Local control was achieved with 94% of NSCLC and 87% of metastases. No serious symptomatic side effects were observed. According to the Kaplan-Meier method the overall survival probability rates of patients with lung metastases were as follows: 1 year: 97%, 2 years: 73%, 3 years: 42%, 4 years: 42%, 5 years: 42% (median survival: 26 months); of those with NSCLC: 1 year: 83%, 2 years: 63%, 3 years: 53%, 4 years: 39%: (median survival: 20.4 months). CONCLUSION: Non-fractionated single-dose irradiation of metastases in the lungs or of small, peripheral bronchial carcinomas is an effective and safe form of local treatment and might become a viable alternative to invasive techniques.
format Text
id pubmed-1579222
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-15792222006-09-28 Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases Fritz, Peter Kraus, Hans-Jörg Mühlnickel, Werner Hammer, Udo Dölken, Wolfram Engel-Riedel, Walburga Chemaissani, Assad Stoelben, Erich Radiat Oncol Research BACKGROUND: We prospectively reviewed response rates, local control, and side effects after non-fractionated stereotactic high single-dose body radiation therapy for lung tumors. METHODS: Fifty-eight patients underwent radiosurgery involving single-dose irradiation. With 25 patients, 31 metastases in the lungs were irradiated; with each of 33 patients, stage I non-small cell lung cancer (NSCLC) was subject to irradiation. The standard dose prescribed to the isocenter was 30 Gy with an axial safety margin of 10 mm and a longitudinal safety margin of 15 mm. The planning target volume (PTV) was defined using three CT scans with reference to the phases of respiration so that the movement span of the clinical target volume (CTV) was enclosed. RESULTS: The volume of the metastases (CTV) varied from 2.8 to 55.8 cm(3 )(median: 6.0 cm(3)) and the PTV varied from 12.2 to 184.0 cm(3 )(median: 45.0 cm(3)). The metastases ranged from 0.7 to 4.5 cm in largest diameter. The volume of the bronchial carcinomas varied from 4.2 to 125.4 cm(3)(median: 17.5 cm(3)) and the PTV from 15.6 to 387.3 cm(3 )(median: 99.8 cm(3)). The bronchial carcinomas ranged from 1.7 to 10 cm in largest diameter. Follow-up periods varied from 6.8 to 63 months (median: 22 months for metastases and 18 months for NSCLC). Local control was achieved with 94% of NSCLC and 87% of metastases. No serious symptomatic side effects were observed. According to the Kaplan-Meier method the overall survival probability rates of patients with lung metastases were as follows: 1 year: 97%, 2 years: 73%, 3 years: 42%, 4 years: 42%, 5 years: 42% (median survival: 26 months); of those with NSCLC: 1 year: 83%, 2 years: 63%, 3 years: 53%, 4 years: 39%: (median survival: 20.4 months). CONCLUSION: Non-fractionated single-dose irradiation of metastases in the lungs or of small, peripheral bronchial carcinomas is an effective and safe form of local treatment and might become a viable alternative to invasive techniques. BioMed Central 2006-08-20 /pmc/articles/PMC1579222/ /pubmed/16919172 http://dx.doi.org/10.1186/1748-717X-1-30 Text en Copyright © 2006 Fritz et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Fritz, Peter
Kraus, Hans-Jörg
Mühlnickel, Werner
Hammer, Udo
Dölken, Wolfram
Engel-Riedel, Walburga
Chemaissani, Assad
Stoelben, Erich
Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases
title Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases
title_full Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases
title_fullStr Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases
title_full_unstemmed Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases
title_short Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases
title_sort stereotactic, single-dose irradiation of stage i non-small cell lung cancer and lung metastases
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1579222/
https://www.ncbi.nlm.nih.gov/pubmed/16919172
http://dx.doi.org/10.1186/1748-717X-1-30
work_keys_str_mv AT fritzpeter stereotacticsingledoseirradiationofstageinonsmallcelllungcancerandlungmetastases
AT kraushansjorg stereotacticsingledoseirradiationofstageinonsmallcelllungcancerandlungmetastases
AT muhlnickelwerner stereotacticsingledoseirradiationofstageinonsmallcelllungcancerandlungmetastases
AT hammerudo stereotacticsingledoseirradiationofstageinonsmallcelllungcancerandlungmetastases
AT dolkenwolfram stereotacticsingledoseirradiationofstageinonsmallcelllungcancerandlungmetastases
AT engelriedelwalburga stereotacticsingledoseirradiationofstageinonsmallcelllungcancerandlungmetastases
AT chemaissaniassad stereotacticsingledoseirradiationofstageinonsmallcelllungcancerandlungmetastases
AT stoelbenerich stereotacticsingledoseirradiationofstageinonsmallcelllungcancerandlungmetastases